Web Results

www.sandsanderson.com/wp-content/uploads/2017/06/Lessons-Learned-from-Implementing-a-Class-Action-Settlement.pdf

April 3, 1998), Koch v. PLM Int'l, Inc.,. 1997 WL 907917 (A.D. Ala. Sept. 24,. 1997) , In re Rezulin Prods. Liab. Litig.,. 168 F. Supp. 2d 136, 147 S.D. N.Y. 2001)). 23. Kirkland et al. v. Wyeth et al.,. Eighth Circuit Court of Appeals, No. 09-. 1205 ( consolidated with Jasperson et al. v. Wyeth et al., No. 09-1250 and Allen et al. v.

supreme.justia.com/cases/federal/us/562/223/opinion.html

RUSSELL BRUESEWITZ, et al., PETITIONERS v. WYETH LLC, fka WYETH, INC., fka WYETH LABORATORIES, et al. on writ of certiorari to the united states court of appeals for the third circuit. [February 22, 2011]. Justice Scalia delivered the opinion of the Court. We consider whether a preemption provision enacted in the  ...

www.americanbar.org/newsletter/publications/aba_health_esource_home/aba_health_law_esource_1104_brown.html

Bruesewitz v. Wyeth's Impact on the Vaccine Safety Debate. By Erin C. Fuse Brown1 & Jalayne J. Arias2, Public Health Law and Policy Program at Sandra Day ... The United States Supreme Court ruled that NCVIA preemptively bars all state-law design-defect claims against vaccine manufacturers.10 Justice Scalia, writing ...

caselaw.findlaw.com/us-8th-circuit/1496608.html

Jan 6, 2010 ... IN RE: Prempro Products Liability Litigation, Rick Jasperson, as Trustee for Next- of-Kin Decedents Gail Gilliam, Marcia Kunkel, Elizabeth Roszak, Mary Solis, Bea Zissel a/k/a Phyllis Bea Zissel, Plaintiff-Appellant, v. Wyeth, and its divisions; Wyeth Pharmaceuticals, Inc.; ESI Lederle; Pfizer, Inc.; Pharmacia ...

onlinelibrary.wiley.com/doi/full/10.1046/j.1365-2036.2003.01756.x

Despite these differences, there are as yet insufficient data to establish the superiority of any one agent over all others across all disease states treated with these agents. ... Adapted from Jadad et al. ..... Table 8 summarizes the comparison of efficacy of omeprazole vs. other proton pump inhibitors not covered in Tables 4–7.

onlinelibrary.wiley.com/doi/pdf/10.1111/j.1365-2036.2006.02952.x

Methods. A representative random sample of 3000 adult inhabitants of northern. Sweden was surveyed using the validated Abdominal Symptom Ques- tionnaire ( response rate 74%). In total, 1001 random responders were endoscoped and assessed using the Short Form-36 Health Survey. Results. Complete data were ...

www.ohsu.edu/xd/research/centers-institutes/evidence-based-practice-center/drug-effectiveness-review-project/upload/PPI-Final-Report-Update-3_MAY_05.pdf

Time to relief of symptoms in trials of esomeprazole vs omeprazole .... 14. Table 5 . Time to relief ...... Jaspersen D, Diehl KL, Schoeppner H, et al. ...... Supported by Wyeth. Ayerst and Wyeth. Lederle. Endoscopic remission at 4 weeks: omeprazole 20 mg: 90% lansoprazole 30 mg: 20% pantoprazole 40 mg: 30%. Recurrence ...

www.ncbi.nlm.nih.gov/pmc/articles/PMC1325125

Oct 27, 2005 ... Objective To evaluate the efficacy of treatment for gastro-oesophageal reflux disease (GORD) on chronic cough in children and adults without an underlying respiratory disease. Design Systematic review and meta-analysis. Data sources Cochrane, Medline, and Embase databases, references from review ...

pdfs.semanticscholar.org/52d8/3135892329b73dd0d0b121363d356f045288.pdf

Jun 21, 2001 ... Rehner M, Rohner HG, Schepp W. Comparison of pantoprazole versus omeprazole in the treatment of acute duodenal ulceration--a multicentre study. Aliment Pharmacol Ther 1995;9:411-6. 18. Beker JA, Bianchi Porro G, Bigard MA et al. Double-blind comparison of pantoprazole and omeprazole for the.